Chronická pankreatitida diagnostikovaná po první atace akutní pankreatitidy - editorial

Antonín Vavrečka

Vnitr Lek 2016, 62(2):87-88  

Kortikosteroidy v léčbě infekčních nemocí - editorial

Jiří Beneš

Vnitr Lek 2016, 62(2):89-91  

Fekální transplantace střevní mikroflóry - editorial

Pavel Polák

Vnitr Lek 2016, 62(2):92-94  

Otrava olovem - editorial

Kamil Vlček

Vnitr Lek 2016, 62(2):95-99  

Chronic pancreatitis diagnosed after the first attack of acute pancreatitis

Martina Bojková, Petr Dítě, Magdalena Uvírová, Nina Dvořáčková, Bohuslav Kianička, Tomáš Kupka, Pavel Svoboda, Pavel Klvaňa, Arnošt Martínek

Vnitr Lek 2016, 62(2):100-104  

Introduction:One of the diseases involving a potential risk of developing chronic pancreatitis is acute pancreatitis. Material:Of the overall number of 231 individuals followed with a diagnosis of chronic pancreatitis, 56 patients were initially treated for acute pancreatitis (24.2 %). Within an interval of 12-24 months from the first attack of acute pancreatitis, their condition gradually progressed to reached the picture of chronic pancreatitis. The individuals included in the study abstained (from alcohol) following the first attack of acute pancreatitis and no relapse of acute pancreatitis was proven during the period...

AT₁-blockers in the treatment of hypertension: summary

Jiří Widimský jr

Vnitr Lek 2016, 62(2):107-113  

Angiotensin receptor antagonists (AT₁-blockers) are considered as one of the major classes of antihypertensive drugs suitable for monotherapy as well as for combination treatment. AT₁-blockers have comparable antihypertensive efficacy with other major classes of antihypertensive drugs. AT₁-blockers are considered by current guidelines of Czech society of hypertension altogether with ACE-inhibitors and calcium channel blockers as universal antihypertensive drug class. AT₁-blockers has the lowest profile of side-effects among all antihypertensive drug classes and thus very high persistence to therapy. Mechanisms...

The patient complains of spinal pain or fatigue and weakness. How do I recognize whether their cause is spondylarthrosis, the patient's age or multiple myeloma?

Zdeněk Adam, Eva Pourová, Luděk Pour, Eva Michalková, Marta Krejčí, Renata Koukalová, Zdeněk Řehák, Jiří Vaníček, Tomáš Nebeský, Hana Petrášová, Sabina Ševčíková, Michal Mašek, Zdeněk Král, Aleš Čermák

Vnitr Lek 2016, 62(2):114-124  

Multiple myeloma has varied manifestations which resemble common patient complaints and that is why this disease is typically not diagnosed until it reaches an advanced stage. Spinal pains can be an expression of deformative and discogenous changes, but also a symptom of multiple myeloma. Pains in the long bones may result from the pain radiating from an arthrotic joint, but also from a large myelomatic osteolytic lesion which makes the bone prone to a spontaneous fracture. Pathological weariness may have many causes, multiple myeloma being one of them. Anemia may have a large number of causes and multiple myeloma is one of them. Raised creatinine...

The rational diagnostic of cholangiocarcinoma

Martin Rydlo, Jana Dvořáčková, Tomáš Kupka, Pavel Klvaňa, Jaroslav Havelka, Magdalena Uvírová, Edvard Geryk, Daniel Czerný, Tomáš Jonszta, Martina Bojková, Vladimír Hrabovský, Veronika Jelínková, Arnošt Martínek, Petr Dítě

Vnitr Lek 2016, 62(2):125-133  

Cholangiocarcinoma (CC) is a rare malignant tumour arising from cholangiocytes, and its prognosis is usually unfavourable, mostly as a result of late diagnosis of the tumour. The current incidence of cholangiocarcinoma in the Czech Republic is 1.4/100,000 inhabitants per year; in less than 30 % of patients with CC, one of the known risk factors can be identified, most frequently, primary sclerosing cholangitis. Only patients with early diagnosed and surgically amenable cholangiocarcinoma are likely to have a longer survival time; in their case, survival for more than five years has been achieved in 20 % to 40 %. From the perspective of the need for...

Use of systemic glucocorticoids in therapy of infectious diseases

Lucie Hromádková

Vnitr Lek 2016, 62(2):134-138  

Glucocorticoids have been known and used in clinical practice for many years now, still their position in the treatment of infectious diseases is continuously developing. Still there are only few review papers focusing on their use in this area. This article summarizes the present knowledge of possible use of glucocorticoids in therapy of infectious diseases. Despite the known contraindication of these agents in the case of acute infections, there have been areas identified where the results of clinical assessments indicate possible benefit. Given the complexity of the problems and sometimes controversial conclusions, each administration of glucocorticoids...

Proton pump inhibitors and their effect on the bone

Markéta Ječmenová, Radek Kroupa

Vnitr Lek 2016, 62(2):139-146  

Introduction:The proton pump inhibitors are commonly used drugs for the treatment of the digestive disorders. Many patients require long-term maintenance therapy. The prolonged acid inhibition is considered to be safe, but recently, the attention has been paid to the possible effects on the bone metabolism and the higher incidence of the fractures in patients using the PPIs.The aim of this work is to give a complex overview on the topic and analyse the source of information about the increased risk of the fractures. Results:Several epidemiological studies describe the incidence of the fractures in the patients...

Fecal microbiota transplantation

Igor Šturdík, Tibor Hlavatý, Juraj Payer

Vnitr Lek 2016, 62(2):147-151  

Fecal microbiota transplantation (FMT) is a therapeutic method, in which the fecal microflora from healthy donors is transmitted to the patient to restore the healthy microbial composition of the gut. In the recent years, there is a growing interest in the therapeutic potential of FMT in various diseases. The standard FMT protocols do not exist. Procedures of FMT vary in several aspects such as donor selection, preparation of fecal material, preparation of the recipient and administration way. FMT appears to be the most successful in the treatment of recurrent Clostridium difficile infection (CDI), randomized controlled studies reported 90 %...

Severe osteoporosis - the story of chronic medication-related hyponatremia

Pavel Polák, Petr Husa, Hana Matějovská Kubešová

Vnitr Lek 2016, 62(2):152-156  

The authors present a case-report of a 73years old woman treated for arterial hypertension within past 15 years with diuretics (thiazides, amiloride and indapamide) and concomitantly with antidepressive trazodone. The patient developed severe osteoporosis after 6 years of such a treatment with multiple fractures even after minor trauma; during whole this period severe hyponatremia without adequate supplementation was documented. Most probably, there exists tight relationship of osteoporosis and hyponatremia in this patient - the authors discuss possible pathophysiological mechanisms at the level of renal tubules, osteoblasts and osteoclasts, hypopituitary-skeletal...

Lead poisoning. A surprising cause of constipation, abdominal pain and anemia

Iva Hoffmanová, Petra Kačírková, Irena Kučerová, Rudolf Ševčík, Daniel Sánchez

Vnitr Lek 2016, 62(2):157-163  

This article reports on patient that has been presented with sudden onset of constipation, abdominal pain and normocytic anemia. Gastroscopy and colonoscopy ruled out an organic diseases. In peripheral blood and bone marrow aspirates mears, coarse basophilic stippling of erythrocyte (and erythroblasts) point out a possibility of heavy metal poisoning. The level of plumbemia exceeded 8.4 times the maximal permitted value for common (non-professional) population. A source of poisoning was indentified from a glaze on a ceramic jug, from which the patient had drank tea with lemon for three months. A lead concentration in the tea extract was 227 mg/kg....

Ivana Štětkářová (ed) et al. Moderní farmakoterapie v neurologii

Karel Urbánek

Vnitr Lek 2016, 62(2):171  

Ladislav Hagara. Ottova encyklopédia húb

Peter Gavorník

Vnitr Lek 2016, 62(2):172  

PRAXBIND® - nová jistota při léčbě perorálním antikoagulanciem PRADAXA®. Zpráva z odborného sympozia Další krok k bezpečnější antikoagulaci pořádaného Českou společností pro trombózu a hemostázu ČLS JEP ve spolupráci se společností Boehringer Ingelheim

Vnitr Lek 2016, 62(2):168-169